Showing 8601-8610 of 8876 results for "".
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,
- Modernizing Medicine and Miraca Life Sciences Partner to Create Enhanced EMR and Pathology Lab Integrationhttps://practicaldermatology.com/news/20130926-modernizing_medicine_and_miraca_life_sciences_partner_to_create_enhanced_emr_and_pathology_lab_integration/2459448/
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the
- Stelara Receives FDA Approval To Treat Active Psoriatic Arthritishttps://practicaldermatology.com/news/20130923-stelara_receives_fda_approval_to_treat_active_psoriatic_arthritis/2459457/The FDA recently approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. For the treatment of psoriatic arthritis, Stelara is administered as a 45
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's
- Caliber Imaging & Diagnostics Introduces VivaScope 1500 Multilaser Systemhttps://practicaldermatology.com/news/20130910-caliber_imaging__diagnostics_introduces_vivascope_1500_multilaser_system/2459465/Caliber Imaging & Diagnostics, formerly Lucid, Inc., recently introduced the VivaScope 1500 Multilaser system, cellular imaging devices that give researchers the option of a painless, no
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/
- Do Physicians Mention Sunscreen Use Often Enough at Patient Visits?https://practicaldermatology.com/news/20130905-do_physicians_mention_sunscreen_use_often_enough_at_patient_visits/2459468/
- Roche's Erivedge OK'd in Canadahttps://practicaldermatology.com/news/20130827-roches_erivedge_okd_in_canada/2459474/Erivedge (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.